Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke

This study has been completed.
Information provided by:
Xijing Hospital Identifier:
First received: December 29, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted

The purpose of this phase 3 study is to validate the efficacy and safety of ginsenoside-Rd for acute ischemic stroke.

Condition Intervention Phase
Ischemic Stroke
Drug: ginsenoside-Rd
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Multicenter Trial

Further study details as provided by Xijing Hospital:

Primary Outcome Measures:
  • the modified Rankin scale [ Time Frame: 90 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • NIHSS scores [ Time Frame: 8 days ] [ Designated as safety issue: No ]
  • NIHSS scores [ Time Frame: 15 days ] [ Designated as safety issue: No ]
  • the Barthel index [ Time Frame: 8 days ] [ Designated as safety issue: No ]
  • the Barthel index [ Time Frame: 15 days ] [ Designated as safety issue: No ]
  • the modified Rankin scale [ Time Frame: 15 days ] [ Designated as safety issue: No ]

Enrollment: 390
Study Start Date: September 2006
Study Completion Date: September 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ginsenoside-Rd 20mg
infusion of ginsenoside-Rd 20mg once a day and continued for 14 days
Drug: ginsenoside-Rd
infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
Other Name: ginsenoside-Rd
Placebo Comparator: placebo
infusion placebo (group B)once a day and continued for 14 days
Drug: placebo
infusion placebo once a day and continued for 14 day
Other Name: placebo

Detailed Description:

A phase Ⅲ randomized, double-blind, placebo-controlled, multicenter study was conducted to examine the efficacy and safety of ginsenoside-Rd in patients with acute ischemic stroke. Stroke patients were randomized equally to receive a 14-day infusion of placebo or ginsenoside-Rd 20mg. Primary end points were NIHSS scores at 15 days. Secondary end points were NIHSS scores and the Barthel index at 8 days, the Barthel index and the modified Rankin scale at 15 days and 90 days. The safety end points included serious and nonserious adverse events, laboratory values and vital signs. Analysis was by intention to treat.


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • between 18 to 75 years
  • the first episode
  • from onset to admission within 72 hours
  • NIHSS scores:5~22

Exclusion Criteria:

  • had other intracranial pathologies (e.g., tumor, infection)
  • had a neurologic or psychiatric disease
  • had a coexisting condition that limited their life expectancy
  • had significant drug or alcohol misuse
  • had high-grade carotid artery stenosis for which surgery was planned
  • were pregnant or nursing
  • participated in a clinical trial with an investigational drug or device within the past 3 months
  • were unlikely to be available for follow-up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00815763

China, Shaanxi
the Department of Neurology , Xijing Hospital
Xi'an, Shaanxi, China, 710032
Sponsors and Collaborators
Xijing Hospital
Study Director: Gang Zhao, MD the Department of Neurology , Xijing Hospital
Study Chair: Xuedong Liu, MD the Department of Neurology, Xijing Hospital
  More Information

No publications provided

Responsible Party: the neurology department of Xijing Hospital, Xijing Hospital Identifier: NCT00815763     History of Changes
Other Study ID Numbers: xijing-002
Study First Received: December 29, 2008
Last Updated: December 29, 2008
Health Authority: China: Food and Drug Administration

Keywords provided by Xijing Hospital:
randomized trial
ischemic stroke

Additional relevant MeSH terms:
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Pathologic Processes
Vascular Diseases processed this record on March 01, 2015